Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human gut metagenome

ABSTRACT: Phase I dose-escalation trial of a fructo-oligosaccharide (FOS) prebiotic in hematopoietic stem cell transplantation recipients

PROVIDER: PRJNA746613 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15417000.fastq.gz	Fastqsanger.gz
	SRR15417000_1.fastq.gz	Fastqsanger.gz
	SRR15417000_2.fastq.gz	Fastqsanger.gz
	SRR15417100.fastq.gz	Fastqsanger.gz
	SRR15417100_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 573

Similar Datasets

Project description:in vitro fermentation of fructo-oligosaccharide, acetylated fructo-oligosaccharide and butyrylated fructo-oligosaccharide

| PRJNA723968 | ENA

The enduring effects of early-life HFHS exposure and microbiota-targeted interventions on blood metabolome in adult female and male mice

Project description:Blood metabolomics of 12-week-old female and male C57BL/6J mice that were exposed to either a control or an unhealthy high-fat/high-sugar (HFHS) diet during early-life, or early-life HFHS diet supplemented with a microbiota-targeted intervention (either a prebiotic combination (fructo-oligosaccharides and galacto-oligosaccharides), FOS+GOS) or a putative probiotic (B. longum APC1472)). The overall aim of the project is to investigate the potential of microbiota-targeted approaches, via prebiotic combination FOS+GOS or the putative probiotic B. longum APC147, to attenuate detrimental enduring effects of an early-life HFHS diet, as a model of western diet, on offspring’s feeding behavior in adulthood.

2026-01-27 | MTBLS12714 | MetaboLights

Proteomics analysis of cerebrospinal fluid (CSF) from multiple sclerosis patients

Project description:Innovative pro-regenerative treatment strategies for progressive multiple sclerosis (PMS), combining neuroprotection and immunomodulation, represents an unmet need. Neural precursor cells (NPCs) transplanted in animal models of multiple sclerosis promote neuroprotection and remyelination by releasing molecules sustaining trophic support and neural plasticity. We present the results of STEMS, a single dose escalation phase I clinical trial, evaluating the feasibility, safety, and tolerability of intrathecally transplanted human fetal NPCs (hfNPCs) in 12 PMS patients.

2022-11-18 | PXD034840 | Pride

Proteomics analysis of cerebrospinal fluid (CSF) from multiple sclerosis patients

2022-11-18 | PXD034846 | Pride

M16-106 adult and pediatric ALL clinical trial - RNAseq dataset

Project description:Combining venetoclax, a selective BCL-2 inhibitor, with low-dose navitoclax, a BCL-XL/BCL-2 inhibitor, may potentiate therapeutic BCL-2 and BCL XL inhibition without dose-limiting thrombocytopenia associated with navitoclax monotherapy. The safety and preliminary efficacy of venetoclax with low-dose navitoclax and chemotherapy was assessed in this phase 1 dose escalation study (NCT03181126) in pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma. Forty-seven patients received treatment. A recommended phase 2 dose of 50 mg navitoclax for adults and 25 mg for patients <45 kg with 400 mg adult-equivalent venetoclax was identified. Delayed hematopoietic recovery was the primary safety finding. The complete remission rate was 60%, including responses in patients who had previously received hematopoietic cell transplantation or immunotherapy. Thirteen (28%) patients proceeded to transplantation or CAR T-cell therapy on study. Venetoclax with navitoclax and chemotherapy was well tolerated and had promising efficacy in this heavily pretreated patient population.

2021-02-17 | GSE162894 | GEO

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial

Project description:Biopsy samples from 4 sites were collected for RNA-Seq and single-cell RNA-Seq from patients with HER2 positive tumors enrolled in a Phase 1 clinical trial of anti-HER2 CAR-macrophage cell therapy. Biopsies of solid tumors were aimed to be collected at screening, 8 days after treatment, and 4 weeks after treatment. Patients in Group 1 received dose escalation of intravenous administration of up to 500 million cells, 1.5 billion cells, and 3 billion cells, on Day 1, 3, and 5, respectively. Patients in Group 2 received their full dose of cells on Day 1. This trial aimed to determine the feasibility of manufacturing CAR-macrophages, as well as assess the safety and tolerability of CAR-macrophage therapy, and determine the severity of potential adverse events.

2025-03-01 | GSE285746 | GEO

GENOMICS TO IDENTIFY HLA IDENTICAL RENAL TRANSPLANT TOLERANCE SIGNATURES

Project description:Immunosuppression is needed in HLA identical sibling renal transplantation. We conducted a tolerance trial in this patient cohort using Alemtuzumab induction, donor hematopoietic stem cells, tacrolimus/mycophenolate immunosuppression converted to sirolimus, planning complete drug withdrawal by 24 months post-transplantation. After an additional 12 months with no immunosuppression, normal biopsies and renal function, recipients were considered tolerant. Twenty recipients were enrolled. Of the first 10 (>36 months post-transplantation), 5 had immunosuppression successfully withdrawn for 16-36 months (tolerant), 2 had disease recurrence and 3 had subclinical rejection in protocol biopsies (non-tolerant). Microchimerism disappeared after 1 year, and CD4+CD25highCD127-FOXP3+ T cells and CD19+IgD/M+CD27- B cells increased to 5 years post-transplantation in both groups, whereas immune/inflammatory gene expression pathways in the peripheral blood and urine were differentially downregulated in tolerant compared to non-tolerant recipients. Therefore, in this HLA identical renal transplant tolerance trial, absent chimerism, Treg and Breg immunophenotypes were indistinguishable between tolerant and non-tolerant recipients, but global genomic changes indicating immunomodulation were observed only in tolerant recipients.

2013-04-01 | GSE45593 | GEO

Characterization of resistance to tumor-localized interleukin-2 and interleukin-12 therapy in pet dogs with advanced malignant melanoma

Project description:Pet dogs with oral melanoma were treated in a dose-escalation trial with collagen-anchored interleukin-2 and interleukin-12 following a single 9Gy dose of radiation therapy. Dogs that progressed during, or after, treatment and were ultimately euthanized had tissue collected from primary and metastatic tumors to analyze gene expression and assess mechanisms of resistance to this therapy.

2024-01-29 | GSE253243 | GEO

Mass spectrometry-based serum biomarker discovery from patients treated with an oncolytic adenovirus encoding TNFα and IL-2 (TILT-123): PROTEOMICS

Project description:Oncolytic viruses represent an emerging therapeutic approach for treating patients with solid tumours. One such virus, TILT-123 (Ad5/3-E2F-D24-hTNFα-IRES-hIL-2), is a serotype chimeric oncolytic adenovirus. TILT-123 is designed to encode tumour necrosis factor alpha and interleukin-2, aiming to induce T-cell infiltration and cytotoxicity within solid tumours. After several years of preclinical development, TILT-123 is now tested in phase I clinical trials either as a monotherapy, or in combination with other T-cell therapies across various solid tumour types. In a single-arm, multicentre phase I dose-escalation trial TUNIMO (NCT04695327), the safety of TILT-123 in patients with advanced solid cancers refractory to standard therapy was evaluated. During the intravenous phase of the study, researchers collected patient serum to identify potential predictive biomarkers associated with intravenous delivery of TILT-123.

2026-02-05 | PXD054594 | Pride

62e41260-3a5f-44f8-a9c2-c2ab5dc9ce86 - samples

Project description:Sixteen patients with refractory solid cancers received up to three distinct neoTCR-transgenic cell products, each expressing a patient-specific neoTCR, in a cell dose-escalation, first-in-human phase 1 clinical trial (NCT03970382). Included are the tumor and normal WXS and tumor RNAseq for dosed patients.

| EGAD00001009830 | EGA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data